MATICAL is a multi-disciplinary organization with more than 15 years of experience providing partnership management for large multidisciplinary projects in the research and innovation fields. MATICAL helps start-up companies, entrepreneurs, universities and research centers shape their R&D exploitation strategy, supporting them also in public and private fundraising processes.
MATICAL’s focus is on the future sustainability of R&D projects, evaluating the potential of their results, both marketable (new technologies, methods, processes, designs) and non-marketable (FAIR data collections), and planning their road-to-market and/or ways towards a long-term contribution to secondary research.
The area of health is where MATICAL has its main focus. MATICAL works with the most relevant actors in the EU health area, including the largest health research institutes, hospitals, public authorities, regulatory bodies, research infrastructures and industry. This includes the new generation of EU biotech companies where Health Data is key, from precision medicine and new drugs discovery to AI-based therapies for cancer and rare diseases. MATICAL supports leading EU biotech enterprises and technology transfer offices in assessing the impact and value of their innovations, carrying out cost-benefit assessments and designing go-to-market strategies for their novel medical devices and related technologies.
Main capabilities relevant to EUCAIM:
BUSINESS MODELLING & SUSTAINABILITY PLANNING
MATICAL offers a holistic approach, bringing in sustainability-by-design concepts at the initial developmental phases of any project, creating synergies with existing initiatives and finding additional financing, all through the project duration. MATICAL is working on projects related to health data of different types (EHR, imaging, omics, patient reported, remotely monitored) helping clear their way to re-use, valuation and exploitation, both in economic and research terms. MATICAL takes the lead in the writing of the project’s sustainability agreement(s), data sharing agreements,
Regarding business modelling, MATICAL can:
– Identify the key exploitable results of a project from a business perspective.
– Propose IPR protection and exploitation strategies.
– Conceptualize appropriate business models, defining the time-to-market, required resources, investments, alliances, and potential revenue streams (public, private, donations, in-kind). Based on co-creation methodologies, involving all the project partners and key stakeholders of the value chain.
– Provide fully documented business plans.
– Provide fully documented financial planning and financial projections.
– Design a PITCH Desk for a product/result/spin-out coming from a project, seeking the investment readiness for the future venture.
– Identify and contact potential investors, further funding opportunities and buyers.
QUANTITATIVE IMPACT OF MEDICAL TECHNOLOGIES
MATICAL carries out studies on the potential impact of results of health R&D projects, including preliminary/prospective health technology assessments (HTA) on Social, Economic, Regulatory, Ethical and Research aspects. MATICAL combines participatory and analytical inputs (considering both the available data and statistics; early project’s results, and the direct input from involved stakeholders -citizens, researchers, technologists, clinicians, regulatory bodies, public authorities….in each specific case) with transnational and networked data. This allows for the involvement of multiple types of institutions from the private, public and civil society sectors, providing opportunities for participation by a broader set of stakeholders and a cross-border approach.
Role of institution in the project
MATICAL is co-leader of WP8 (Sustainability) and a member of the Project Coordination Team.
In WP8, MATICAL leads the definition of the future EUCAIM business model (BM) and its complete Financial Plan (FP). The BM task foresees the initial definition of all the BM components and their testing during the last phase of the project. A co-creation approach will be taken during this task. Different interviews with representatives from the main customer segments identified in EUCAIM are planned. The FP task foresees the creation of a complete financial plan for the future research infrastructure.
